NVX 408Alternative Names: NVX-408
Latest Information Update: 31 May 2016
At a glance
- Originator NuvOx Pharma
- Class Fluorocarbons
- Mechanism of Action Oxygen carriers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haemorrhagic shock
Most Recent Events
- 31 May 2016 Phase-I clinical trials in Haemorrhagic shock (IV) in USA before May 2016
- 31 Aug 2014 Preclinical trials in Haemorrhagic shock in USA (IV) before August 2014